Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

PHARMNeutralEarningsShort Term

High materiality9/10

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

StockNews.AIJul 30, 1:00 AM EDT1 source

Trading thesisImportance 9/10

Near-term neutral to modestly bullish on EU launches and CVID data; upside if Q4 leniolisib readouts meet expectations.

AI summary

What happened and why it matters

Pharming reported 2Q26 revenue of $90.2 million, with RUCONEST at $72.3 million and Joenja at $17.9 million, underscoring RUCONEST resilience and growing leniolisib uptake in APDS. The company lowered full-year revenue guidance to $375-395 million while signaling RUCONEST stabilization and Joenja growth in H2 2026, supported by Germany's EU launch and upcoming CVID data readouts in Q4 2026.

Joenja launches in Germany on July 1, 2026; Canada and Korea approvals follow in July 2026.
FDA pediatric sNDA for Joenja accepted; PDUFA date set for October 24, 2026.
2026 revenue guidance reduced to US$375-395 million; operating expenses guided to US$315-320 million.
APDS patient pool identified at 1,042 globally; 132 on paid therapy in the U.S. as of 6/30/2026.

Sentiment rationale

Guidance reduction introduces near-term headwinds, but multiple catalysts (Germany launch, other regulatory approvals, Q4 CVID data) offer upside potential. The net effect likely keeps PHARM in a trading range until clearer data emerge in late 2026.

Key facts

01
2Q26 revenue $90.2m, down 3% YoY; RUCONEST $72.3m, Joenja $17.9m.
02
France site closure drives $1.7m one-time costs; adjusted op profit $7.9m.
03
Guidance cut: 2026 revenue $375-395m; expenses $315-320m.
04
Joenja launches Germany; Canada and Korea approvals; CVID data readouts in Q4 2026.

Earnings

Earnings. The piece centers on quarterly results, updated guidance, and pipeline/regulatory milestones for Pharming's two marketed assets and leniolisib development.